Sibutramine--a review of clinical efficacy.

摘要: Controlled studies have shown that sibutramine produces dose-related weight loss when given in the range 5-30 mg per day, with optimal doses of 10 and 15 day. Weight is 3-5 kg better than placebo at 24 weeks, maintained to 52 weeks mg. By six months, 69% patients treated achieve a 5% or greater reduction their baseline weight. The achieved was similar dexfenfluramine over 12 (4.5 compared 3.2 kg). Sibutramine-induced has been found be accompanied by significant waist/hip ratio, decreases plasma triglycerides, total cholesterol low density lipoprotein (LDL) cholesterol. There were also increases high (HDL) In type II diabetes, sibutramine-induced shift towards improved glycaemic control. controlled studies, 84% sibutramine-treated reported adverse events, 71% receiving placebo. most frequently events are related pharmacological actions sibutramine, include dry mouth, decreased appetite, constipation insomnia.